This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy  • Adverse Effects  • Genetics  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2008;300(7):782.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Scientists in England have identified a genetic variant that is strongly associated with an increased risk of myopathy related to statin use (The SEARCH Collaborative Group. N Engl J Med. 10.1056/NEJMoa0801936 [published online ahead of print July 23, 2008]).

The study focused on 85 persons with definite or incipient myopathy and 90 controls, all of whom were taking 80 mg of simvastatin daily as part of a trial involving about 12 000 participants. A particular variant of a gene called SCLO1B1, which encodes a protein that regulates the uptake of statins, was associated with more than 60% of cases of myopathy. Those with 1 copy of this variant, the C allele, were more than 4 times likelier to have myopathy compared with individuals who possess a more common variant of SCLO1B1, the T allele; those with 2 C alleles were about 17 times more likely . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?